Wall Street analyst estimates for BioCardia, Inc. (BCDA): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
BioCardia, Inc. is a pioneering clinical-stage company dedicated to regenerative medicine, focusing on the development of advanced cellular and cell-derived therapies for a range of cardiac and respiratory ailments. Central to its pipeline is the CardiAMP Cell Therapy System, designed to address heart failure and chronic myocardial ischemia. Additionally, BioCardia is advancing an allogeneic cell therapy program, also targeting cardiac and pulmonary conditions.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 4 |
| Hold | 1 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 5 |
| Avg rating (1-5) | 0.80 |
Valuation Ratios
| Price / Book | 10.78 |
| EV / EBITDA | -0.82 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $576000 | $479000 | $625000 | $710000 | $145000 | $1.0M | $1.4M | $477000 | $58000 | 0 |
| Cost of Revenue | $746000 | $690000 | $517000 | $358000 | $4000 | $640000 | $8.8M | $7.7M | $4.4M | $505000 |
| Gross Profit | -$170000 | -$211000 | $108000 | $352000 | $141000 | $375000 | -$7.5M | -$7.2M | -$4.3M | -$505000 |
| Research & Development | $3.3M | $5.8M | $8.5M | $8.6M | $9.8M | $8.6M | $8.8M | $7.7M | $4.4M | $5.0M |
| Selling, General & Admin | $4.1M | $6.4M | $5.8M | $6.0M | $5.9M | $5.1M | 0 | 0 | 0 | $3.3M |
| Operating Expenses | $7.4M | $12.2M | $14.2M | $14.6M | $15.7M | $13.0M | $4.4M | $4.4M | $3.7M | $7.8M |
| Operating Income | -$7.6M | -$12.4M | -$14.1M | -$14.2M | -$15.5M | -$12.6M | -$11.9M | -$11.6M | -$8.0M | -$8.3M |
| EBITDA | -$8.5M | -$12.2M | -$13.9M | -$14.0M | -$14.4M | -$12.6M | -$11.8M | -$11.5M | -$7.9M | -$7.7M |
| Interest Expense | $1.7M | 0 | 0 | $112000 | $3000 | 0 | $6000 | 0 | 0 | 0 |
| Pre-tax Income | -$10.3M | -$12.3M | -$14.0M | -$14.7M | -$15.0M | -$12.6M | -$11.9M | -$11.6M | -$7.9M | -$8.2M |
| Income Tax | 0 | 0 | -$115000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$10.3M | -$12.3M | -$14.0M | -$14.7M | -$15.0M | -$12.6M | -$11.9M | -$11.6M | -$7.9M | -$8.2M |
| EPS | $-166.33 | $-43.50 | $-48.80 | $-39.15 | $-22.20 | $-11.19 | $-10.05 | $-8.19 | $-2.90 | $-1.23 |
| EPS (Diluted) | $-166.33 | $-43.50 | $-48.80 | $-39.15 | $-22.20 | $-11.19 | $-10.05 | $-8.19 | $-2.90 | $-1.23 |
| Shares Outstanding (Diluted) | $61987 | $282671 | $284279 | $376289 | $674579 | $1.1M | $1.2M | $1.4M | $2.7M | $6.7M |
Price
| Price | $1.25 |
| Market Cap | $19M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ACXP · ADIL · ALZN · APRE · APVO · CELZ · HCWB
Explore sector: Healthcare · Biotechnology
More sections of BCDA: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks